An 8 Week Study Looking At The Efficacy, Toleration And Safety Of SS-RBX For Stress Urinary Incontinence.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00138749|
Recruitment Status : Completed
First Posted : August 30, 2005
Last Update Posted : April 7, 2011
|Condition or disease||Intervention/treatment||Phase|
|Urinary Incontinence, Stress||Drug: SS-RBX||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||402 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||An 8-Week, Multi-Centre,Randomised Double-Blind, Placebo Controlled, Parallel Group Study To Evaluate The Efficacy,Toleration And Safety Of (+)- [S,S]- Reboxetine In The Treatment Of Stress Urinary Incontinence (SUI) In Women.|
|Study Start Date :||November 2004|
|Actual Primary Completion Date :||August 2006|
|Actual Study Completion Date :||August 2006|
- Proof of concept study to assess the efficacy, tolerability and safety of SS-RBX vs. placebo in the treatment of SUI.
- To evaluate whether an upward dose adjustment affects the tolerability of SS-RBX.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00138749
Show 95 Study Locations
|Study Director:||Pfizer CT.gov Call Center||Pfizer|